The OPIE Transducer is designed to evaluate the ventricular septal thickness of a patient using real-time imaging visualisation during septal myectomy surgery
Fujifilm introduces OPIE Transducer for septal myectomy. (Credit: jesse orrico on Unsplash)
Fujifilm Healthcare Americas has introduced OPIE Transducer for on-pump intracardiac echocardiography (OPIE) in septal myectomy surgeries.
The OPIE Transducer is designed to assess the ventricular septal thickness in septal myectomy surgery by offering imaging visualisation in real time.
The technology includes a thin transducer passed into the heart to generate real-time images of the patient’s septal thickness.
A study showcasing Fujifilm’s OPIE Transducer established its effectiveness in providing imaging support for septal myectomy procedures compared to transoesophageal echocardiography (TEE) and transthoracic echocardiogram (TTE).
According to Fujifilm, the real-time measurement of interventricular septal thickness prevents creating a ventricular septal defect while resecting sufficient myocardium.
Additionally, the OPIE Transducer integrates easily with Fujifilm’s ultrasound platform, the ARIETTA Precision.
The device is currently available in the US and awaiting regulatory clearance in Canada.
Fujifilm Healthcare Americas ultrasound solutions vice president Hideyuki Honda said: “During septal myectomy, it is critical to correctly measure the patient’s septal thickness because it can directly impact the patient’s care pathway.
“Every day we pride ourselves on delivering what we believe is the highest quality ultrasound solutions, arming cardiologists and cardiothoracic surgeons alike with the visualisation they need to eliminate guess work in the operating room.
“Early clinical results of our OPIE Transducer during a high-risk procedure like cardiac bypass surgery are impressive, and we’re proud that the technology is proving to provide high-quality, real-time feedback for the surgeon.”
The American unit of Tokyo-based Fujifilm is also planning to unveil the ELUXEO Vision device during the ongoing 104th American Association for Thoracic Surgery (AATS) meeting in Toronto, Canada.
ELUXEO Vision has received breakthrough device designation from the US Food and Drug Administration (FDA). It has been designed to deliver real-time tissue oxygenation visualisation for laparoscopic and endoscopic applications.
The device also facilitates the evaluation of tissue oxygen saturation.
Last month, Fujifilm Healthcare Americas secured the FDA 510(k) clearance for CAD EYE, an artificial intelligence-powered detection endoscopic imaging system.